|Jeffrey A. Lieberman|
|Residence||New York City|
|Alma mater||George Washington University Medical School, Saint Vincent's Catholic Medical Center|
|Known for||Schizophrenia research, NIMH CATIE study|
|Awards||Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders; the Adolph Meyer Award from the American Psychiatric Association; the Research Award from the National Alliance on Mental Illness, and the Neuroscience Award from the International College of Neuropsychopharmacology|
|Institutions||American Psychiatric Association, Columbia University, New York State Psychiatric Institute, University of North Carolina School of Medicine, Mount Sinai School of Medicine, Albert Einstein College of Medicine, Zucker Hillside Hospital of Long Island Jewish Medical Center|
Jeffrey Alan Lieberman (born 1948) is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience (biology) and drugs. He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing therapies for schizophrenia.
Lieberman is the Lawrence E. Kolb Professor and chairman of psychiatry at the Columbia University College of Physicians and Surgeons and director of the New York State Psychiatric Institute. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as the psychiatrist in chief of NewYork-Presbyterian Hospital-Columbia University Medical Center.
Education and early career
Lieberman graduated from Miami University in 1970, and then received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent's Hospital and Medical Center of New York Medical College, he was on the faculties of the Mount Sinai School of Medicine and Albert Einstein College of Medicine, and served as director of research at the Zucker Hillside Hospital of Long Island Jewish Medical Center.
Prior to moving to Columbia University, he was vice chairman for Research and Scientific Affairs in the UNC Department of Psychiatry and Director of the Mental Health and Neuroscience Clinical Research Center at the University of North Carolina at Chapel Hill School of Medicine.
Lieberman's research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.
Lieberman served as principal investigator for Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental Health (NIMH). The investigators compared a, "first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study". "Probably the biggest surprise of all was that the older medication produced about as good an effect as the newer medications, three of them anyway, and did not produce neurological side effects at greater rates than any of the other drugs," Lieberman told The New York Times.
Lieberman's work has been reported in more than 450 articles in the scientific literature and he has edited or co-edited eight books, including the textbook Psychiatry, currently in its second edition, Textbook of Schizophrenia, Comprehensive Care of Schizophrenia, Psychiatric Drugs and Ethics in Psychiatric Research: A Resource Manual on Human Subjects Protection.
He also serves, or has served, as associate editor of the American Journal of Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Acta Psychiatrica Scandinavica, Schizophrenia Research, NeuroImage, The International Journal of Neuropsychopharmacology, and Schizophrenia Bulletin.
Awards, honors, and memberships
Lieberman is a member of the National Academy of Sciences Institute of Medicine and a fellow of the American Association for the Advancement of Science (AAAS). He received the Lieber Prize for Schizophrenia Research from NARSAD, the Adolph Meyer Award from the American Psychiatric Association (APA), the Stanley R. Dean Award for Schizophrenia Research from the American College of Psychiatrists, the APA Research Award, the APA Kempf Award for Research in Psychobiology, the APA Gralnick Award for Schizophrenia Research, the Ziskind-Somerfeld Award of the Society of Biological Psychiatry, the Ernest Strecker Award of the University of Pennsylvania, the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research, the Scientific Research Award and the Exemplary Psychiatrist Award from the National Alliance on Mental Illness, the Ed Hornick Memorial Award of The New York Academy of Medicine, the Strecker Award of the Department of Psychiatry at the University of Pennsylvania.
He is or has been a member of the advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General's Report on Mental Health, the Committee on Research on Psychiatric Treatments of the APA, the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee, the National Advisory Mental Health Council of the NIMH, and currently chairs the APA Council of Research.
Conflict of Interest
This section contains information of unclear or questionable importance or relevance to the article's subject matter. (January 2018) (Learn how and when to remove this template message)
Lieberman's work necessitates[According to who?] close work with many leading pharmaceutical companies, and raises questions of improper conduct due to extrajudicial funding. Lieberman has consistently filed disclosure of his funding and has not been accused of any undisclosed improprieties.
On multiple occasions, Lieberman has publicly disclosed information about potential conflicts of interest. This has included a 2006 letter to the editor of the Wall Street Journal, a 2007 release in Primary Psychiatry, and a 2009 disclosure to the American College of Neuropsychopharmacology.
Lieberman's most recent conflict of interest disclosure came in 2013. As of June 2013, as disclosed in Annals of Internal Medicine, the British Journal of Psychiatry, and JAMA, Lieberman's disclosure of financial conflict of interest is on file with the International Committee of Medical Journal Editors (ICMJE).
A note on "competing interests" for contributors to his Essentials of Schizophrenia (2011) stated that Lieberman received no direct financial compensation for his research, consulting and advisory board activities other than Intra-Cellular Therapies.
This section's tone or style may not reflect the encyclopedic tone used on Wikipedia. (January 2018) (Learn how and when to remove this template message)
Lieberman has received criticism from an ex-patient for his demeanor and his close ties to the pharmaceutical industry. He has also removed anti-psychotic drugs from patients and gave them psychogenic drugs in experiments.
- "Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)". National Institute of Mental Health. 2005 to 2008. Retrieved May 26, 2013. Check date values in:
- "Questions and Answers About the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness Study (CATIE) — Phase 1 Results". National Institute of Mental Health, U.S. Department of Health and Human Services. September 2005. Retrieved May 28, 2013.
- "Jeffrey A. Lieberman". Columbia University. Retrieved May 26, 2013.
- "Jeffrey Lieberman, M.D." Columbia University Department of Psychiatry. 2005 to 2008. Retrieved May 26, 2013. Check date values in:
- Lieberman, Jeffrey A.; et al. (September 22, 2005). "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia". The New England Journal of Medicine. Massachusetts Medical Society. 353 (12): 1209–1223. doi:10.1056/NEJMoa051688. PMID 16172203.
- Carey, Benedict (September 20, 2005). "Little Difference Found in Schizophrenia Drugs". The New York Times. Retrieved May 30, 2013.
- "Prestigious Lieber Prize for Research Awarded to Jeffrey A. Lieberman, M.D". National Institute of Mental Health. October 12, 2006. Retrieved May 26, 2013.
- "Reception and Presentation of the 2011 NAMI Scientific Research Award". National Alliance on Mental Illness. Retrieved May 26, 2013.
- "Jeffrey A. Lieberman Receives Hornick Award; Delivers Lecture on Early Interventions for Schizophrenia". The New York Academy of Medicine. January 12, 2012. Retrieved May 26, 2013.
- "Previous Strecker Award Recipients". The Trustees of the University of Pennsylvania. Retrieved May 26, 2013.
- "2 letters Re: Dr. Nemeroff Failure to Disclose Conflicts of Interest_WSJ". Alliance for Human Research Protection. September 22, 2006. Retrieved May 27, 2013.
- "2009 ACNP Annual Meeting Disclosures". American College of Neuropsychopharmacology. Retrieved May 27, 2013.
- ICMJE FCOI Form[dead link]
- Lieberman, Jeffrey A.; et al. (2011). Essentials of Schizophrenia. American Psychiatric Pub via Google Books. p. xiii. ISBN 1585624012.
- Stone, Judy (May 24, 2013). "Anti-Psychiatry Prejudice? A response to Dr. Lieberman". Scientific American. Retrieved May 30, 2013.
- "CAFE Comparison of Atypicals in First Episode of Psychosis: ClinicalTrials.gov Identifier NCT00034892 (completed)". U.S.National Institutes of Health. May 2, 2002 to March 2005. Retrieved May 30, 2013. Check date values in:
- "Methylphenidate challenge as a predictor of relapse in schizophrenia." Authors Jeffrey Lieberman, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B. Am J Psychiatry. 1984 May,141(5):633-8. PMID 6143506 doi:10.1176/ajp.141.5.633
- "Prediction of relapse in schizophrenia." Authors Jeffrey Lieberman,Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J. Arch Gen Psychiatry. 1987 Jul 44(7):597-603. PMID 2886110
- "Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia". Authors Jody D, Jeffrey Lieberman, Geisler S, Szymanski S, Alvir JM. Psychopharmacol Bull. 1990;26(2):224-30. PMID 2236460
- "Mood responses of remitted schizophrenics to methylphenidate infusion"]. Authors Robinson D, Mayerhoff D, Alvir J, Cooper T, Jeffrey Lieberman. Psychopharmacology 1991;105(2):247-52. PMID 1796130
- "Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia."Authors Jeffrey Lieberman,Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM. Neuropsychopharmacology. 1994 Oct,11(2):107-18. PMID 7840862 doi:10.1038/npp.1994.40
- "The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls." Authors Koreen , Jeffrey Lieberman, Alvir J, Chakos M. Neuropsychopharmacology. 1997 Jan;16(1):61-8. PMID 8981389 doi:10.1016/S0893-133X(96)00160-1
- "Rainbow Light Home". Blessed Herbs. Retrieved 2016-12-14.
- "Jeffrey Lieberman, M.D." clintara.com. Retrieved 2016-12-14.